Group items matching

in title, tags, annotations or url

The Department of Defense (DoD) announces the Fiscal Year 2020 Defense University Research Instrumentation Program (DURIP). DURIP is designed to improve the capabilities of accredited United States (U.S.) institutions of higher education to conduct research and to educate scientists and engineers in areas important to national defense, by providing funds for the acquisition of research equipment or instrumentation. For-profit organizations are not eligible for DURIP funding. We refer to eligible institutions of higher education as universities in the rest of this announcement. DURIP is part of the University Research Initiative (URI).

The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fieldsneuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry.

The purpose of this FOAs are to encourage mechanistic research to investigate the impact of sleep disturbances on chronic pain. The mechanisms and processes underlying the contribution of sleep disturbances to chronic pain development and maintenance may be very broad. This FOA encourages interdisciplinary collaborations by experts from multiple fieldsneuroscientists, psychologists,endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry.

The PRMRP Investigator-Initiated Research Award (IIRA) is intended to support studies that will make an important contribution toward research and/or patient care for a disease or condition related to at least one of the FY19 PRMRP Topic Areas. The rationale for a research idea may be derived from a laboratory discovery, population-based studies, a clinician's first-hand knowledge of patients, or anecdotal data. Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished or from the published literature

The intent of the PRMRP Discovery Award is to support innovative, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies, or applications. Studies supported by this award are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on a sound scientific rationale and study design. The anticipated direct costs budgeted for the entire period of performance for an FY19 PRMRP Discovery Award will not exceed $200,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

The Therapeutic Idea Award is designed to promote new ideas aimed at drug or treatment discovery that are still in the early stages of development. Projects that focus primarily on investigating the pathophysiology of ALS are not within the scope of this Funding Opportunity. Development and/or modification of preclinical model systems or the application of high- throughput screens to define or assess lead compounds for ALS treatment are of interest. Development of methods to adequately measure target binding and proximal downstream effects (target engagement) and the potential for undesirable activities at related but unintended targets (selectivity) are also encouraged. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data, but on the innovative approach. All proposed research projects should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality. Innovation and impact are important aspects of the Therapeutic Idea Award. Research deemed innovative may introduce a new paradigm, challenge current paradigms, introduce novel concepts or technologies, or exhibit other uniquely creative qualities that may lead to potential therapeutics for ALS. Impact may be near-term or long-term, but must be significant and move beyond an incremental advancement.

This Funding Opportunity Announcement (FOA) solicits research grant applications which will: 1) advance measurements of intersectional stigma (multiple stigmatized identities) and examine the mechanisms and pathways by which it is a barrier to HIV testing and linkage to prevention; or 2) develop and test interventions to reduce intersectional stigma and improve the uptake of HIV testing and linkage to ongoing HIV prevention among key populations at substantial risk for HIV infection. RFA-MH-19-412 uses the R01 grant mechanism, and RFA-MH-19-410 uses the R34 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. Applicants with preliminary data and/or include longitudinal analysis may be appropriate for the R01 mechanism. Applicants proposing to develop and pilot test an intervention should consider using the R34 mechanism.

The International Research Experiences for Students (IRES) program supports international research and research-related activities for U.S. science and engineering students. The IRES program contributes to development of a diverse, globally-engaged workforce with world-class skills. IRES focuses on active research participation by undergraduate or graduate students in high quality international research, education and professional development experiences in NSF-funded research areas. The overarching, long-term goal of the IRES program is to enhance U.S. leadership in research and education and to strengthen economic competitiveness through training the next generation of research leaders. This solicitation features three mechanisms; proposers are required to select one of the following tracks to submit their proposal. Track I focuses on the development of world-class research skills in international cohort experiences. Track II is dedicated to targeted, intensive learning and training opportunities that leverage international knowledge at the frontiers of research. Track III supports U.S. institutional collaborations to develop, implement and evaluate innovative models for high-impact, large-scale international research and professional development experiences for U.S. graduate students. Student participants supported by IRES funds must be citizens, nationals, or permanent residents of the United States. Students do not apply directly to NSF to participate in IRES activities. Students apply to NSF-funded investigators who receive IRES awards. To identify appropriate IRES projects, students should consult the directory of active IRES awards. All PIs, co-PIs and Senior Personnel on IRES proposals must be from U.S. based institutions.

The purpose of this funding opportunity announcement (FOA) is to support research to continue the development of drug development tools that have an accepted Letter of Intent within CDER's Drug Development Tool Qualification Program.

The Michael J. Fox Foundation believes that a major hurdle in the development of promising treatments for Parkinson's disease is the need for well-validated targets linked to the disease process. By promoting critical target validation studies within academic and industry laboratories, MJFF investments can help de-risk subsequent drug development and ultimately accelerate the creation of innovative therapies for Parkinson's patients. Part of our Edmond J. Safra Core Programs for PD Research, the Target Advancement program seeks to build robust evidence to rationalize biological pathways and targets for further translation into new Parkinson's treatments.

The Michael J. Fox Foundation believes that a major hurdle in the development of promising treatments for Parkinson's disease is the need for well-validated targets linked to the disease process. By promoting critical target validation studies within academic and industry laboratories, MJFF investments can help de-risk subsequent drug development and ultimately accelerate the creation of innovative therapies for Parkinson's patients. Part of our Edmond J. Safra Core Programs for PD Research, the Target Advancement program seeks to build robust evidence to rationalize biological pathways and targets for further translation into new Parkinson's treatments.

This funding opportunity announcement (FOA) encourages applications from institutions/organizations that propose to develop informative outcome measures for use in clinical trials for individuals with intellectual and developmental disabilities (IDD). This FOA will address a significant need in the field, one that is especially apparent in efforts to develop pharmacological treatments for these populations. This FOA will focus ongoing clinical and translational research on a neglected area essential for therapy and pharmacological treatment development. Potential applicants may also be interested in the FOA Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities (R01).

This Funding Opportunity Announcement (FOA) invites applications to establish Compound Identification Development Cores (CIDC) to develop innovative approaches to enhance compound identification of the most significant, biomedically-relevant unknown metabolites. The ultimate goal of this FOA is to expand the repertoire of biologically relevant compounds that can be quickly and inexpensively identified in high throughput metabolomics experiments. An interdisciplinary approach and partnership among metabolomics experts, biomedical researchers, chemists, and computational experts will be integral to the success of this goal, and advances made through this initiative are expected to be catalytic to the field.

The purpose of this funding opportunity announcement (FOA) is to promote the discovery of novel small molecules that may enhance the ability of the immune system to selectively recognize and attack cancer cells. These small molecules could be further developed into stand-alone immunotherapeutics or synergistic partners for existing therapies, or as chemical probes for the discovery and validation of novel targets involved in anti-tumor immunity. Investigators from multiple scientific disciplines (immuno-oncology, tumor biology, screening technology, medicinal chemistry, and pharmacology) are encouraged to establish collaborative teams to discover and develop novel small molecule immunomodulators for cancer therapy. This FOA encourages the design of research projects that utilize the following phases of discovery research: 1) assay development specifically designed for immuno-oncology targets with the intent to screen for novel small molecule compounds that show potential as either probes or drugs, or as pre-therapeutic leads; 2) screen implementation for immunomodulatory targets to identify initial screening hits (from high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches); 3) hit validation through secondary orthogonal and counter screening assays, and hit prioritization; and 4) hit-to-lead optimization.

We envision that studies funded by this Research RFP will fall into one the following key areas: · Studies focused on the molecular and biochemical mechanisms regulating SMN expression or mediating SMN function. Results should lead to a better understanding of the requirements for SMN protein biologically. There is a particular interest in identifying genetic modifiers, upstream regulators of SMN expression / splicing / function, and downstream effectors of SMN functional activity, resulting in new drug targets for SMA. · Studies resulting in greater understanding of the pathophysiology of SMA, using well-validated animal or cellular models of the SMA. This includes focus on the tissue or timing requirements for SMN protein, the cellular autonomy of the disease in motor neurons and other cells, peripheral versus central manifestations of SMA, and others. · Studies focused on early proof-of concept assessment of novel therapeutic approaches for SMA in well-validated animal or cellular models of the disease or on progressing aspects of ongoing preclinical drug programs for SMA towards IND. Proposed SMN enhancing approaches should have advantage over current candidates or have the ability to be used in combination. Particular interest exists in non-SMN based approaches with the potential for combination use with SMN up-regulation strategies. · Work focused on generating research or clinical trial tools for SMA, such as new animal models, phenotypic cellular assays, activity assays for SMN function, biomarkers or outcome measures for clinical trials, and newborn screening protocols / technologies.

To that end, the two organizations have issued a Request for Applications for projects that test feasibility and generate preliminary data. MRA and ACS have each committed $1 million for the awards. The combined $2 million will be used to fund Multidisciplinary Team Awards and Pilot Awards. 1) Multidisciplinary Team Awards: At least one grant of up to $1 million will be awarded in this category are designed to foster interdisciplinary collaborative research to promote transformational advances with the potential for rapid clinical benefit. Letters of Intent must be received no later than August. Upon review, selected applicants will be invited to submit full applications by October 31, 2017. 2) Pilot Awards: Up to five grants of up to $200,000 each will be awarded over two years to help seed the ground in this relatively young area of checkpoint irAE research. Applications must be received no later than October 16, 2017.

The mission of the Defense Advanced Research Projects Agency (DARPA) Defense Sciences Office (DSO) is to identify and pursue high-risk, high-payoff research initiatives across a broad spectrum of science and engineering disciplines and to transform these initiatives into disruptive technologies for U.S. national security. In support of this mission, the DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts that address one or more of the following technical domains:

The Research Experiences for Undergraduates (REU) program supports active research participation by undergraduate students in any of the areas of research funded by the National Science Foundation. REU projects involve students in meaningful ways in ongoing research programs or in research projects specifically designed for the REU program. This solicitation features two mechanisms for support of student research: (1) REU Sites are based on independent proposals to initiate and conduct projects that engage a number of students in research. REU Sites may be based in a single discipline or academic department or may offer interdisciplinary or multi-department research opportunities with a coherent intellectual theme. Proposals with an international dimension are welcome. (2) REU Supplements may be included as a component of proposals for new or renewal NSF grants or cooperative agreements or may be requested for ongoing NSF-funded research projects.

The Catalysis program is part of the Chemical Process Systems cluster, which also includes: 1) the ElectroChemical Systems program; 2) the Interfacial Engineering program; and 3) the Process Systems, Reaction Engineering, and Molecular Thermodynamics program. The goals of the Catalysis program are to increase fundamental understanding in catalytic engineering science and to advance the development of catalytic materials and reactions that are beneficial to society. Research in this program should focus on new concepts for catalytic materials and reactions, utilizing synthetic, theoretical, and experimental approaches. Target applications include fuels, specialty and bulk Chemicals, environmental catalysis, biomass conversion to fuels and Chemicals, conversion of greenhouse gases, and generation of solar hydrogen, as well as efficient routes to energy utilization. Heterogeneous catalysis represents the main thrust of the program. Proposals related to both gas-solid and liquid-solid heterogeneous catalysis are welcome, as are proposals that incorporate concepts from homogeneous catalysis. Topic areas that are of particular interest include: · Renewable energy-related catalysis with applications in electrocatalysis, photocatalysis, and catalytic conversion of biomass-derived Chemicals. Catalysis aimed at closing the carbon cycle (especially conversion of CO2, methane, and natural gas to fuels and Chemical intermediates). · Catalytic alternatives to traditionally non-catalytic reaction processes, as well as new catalyst designs for established catalytic processes. · Environmental catalysis (including energy-efficient and green routes to fuels and Chemicals). ·

TheDisability and Rehabilitation Engineeringprogram is part of the Engineering Biology and Health cluster, which also includes: 1) the Biophotonics program; 2) the Biosensing program; 3) the Cellular and Biochemical Engineering program; and 4) the Engineering of Biomedical Systems program. TheDisability andRehabilitation Engineeringprogram supports fundamental engineering research that will improve the quality of life of persons with disabilities through: development of new technologies, devices, or software; advancement of knowledge regarding healthy or pathological human motion; or understanding of injury mechanisms. Research may be supported that is directed toward the characterization, restoration, rehabilitation, and/or substitution of human functional ability or cognition, or to the interaction between persons with disabilities and their environment. Areas of particular interest are neuroengineering and rehabilitation robotics. The program will also consider research in the areas of: new engineering approaches to understand healthy or pathological motion, both as a target for rehabilitation and as a means to characterize motion related to disability or injury; understanding injury at the tissue- or system-level such that interventions may be developed to reduce the impact of trauma and subsequent disability; or understanding the role of gut microbiota in modulating disability in the context of rehabilitation. Emphasis is placed on significant advancement of fundamental engineering knowledge that facilitates transformative outcomes.

This Funding Opportunity Announcement (FOA) solicits R21 grant applications to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Applicants may propose to develop novel complete synthesis and/or synthetic constructs systems, investigate challenges underlying key novel system components, or propose substantive improvements of at least an order of magnitude improvement to existing systems. Exploration of methods other than those currently in use is highly encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.